ClinicalTrials.gg
CompletedNCT01870921DaYuUpdated Apr 3, 2018Results posted

Brilinta DaYu Study

A Phase 4 interventional study of Ticagrelor in Acute Coronary Syndrome, sponsored by AstraZeneca. Completed at 39 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-04-03.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,004
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.

Enrollment
12th of 67
2,004 · median 120
Started
2013
with 7 others
Phase 4
38 of 67
5 open now
Registered
15th of 67
by date
Lead sponsor
8 of 67
AstraZeneca

Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 12th largest by enrollment, is one of 8 that started in 2013, is one of 38 in phase 4, and was the 15th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing ticagrelor in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the incidence of major cardiovascular events of ticagrelor in Chinese patients with acute coronary syndrome

03

Conditions studied

  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Female or male aged at least 18 years 2.Index event of non-ST or ST segment elevation ACS 3.A patient who is considered as ethnic Chinese

Exclusion criteria

Exclusion Criteria:

    1. With coagulation disorder 2.Index event is an acute complication of PCI 3.Patient has planned for an urgent coronary artery bypass graft (CABG) within 7days from the enrolment 4.Oral anticoagulation therapy within 30 days prior to enrolment or cannot be stopped 5.Increased risk of bradycardic events 6. Concomitant oral or intravenous therapy (see examples below) with strong inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers 7.Increased risk of bradycardic events (eg, no pacemaker and known sick sinus syndrome, second degree A-V block, third degree A-V block or previous documented syncope suspected to be due to bradycardia unless treated with a pacemaker). 8.Known thrombocytopenia 9.Known clinically important anaemia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,004 participants (actual)

Study arms

  • Experimental
    Ticargrelor

    90 mg/tablet, 1 tablet bid

    Drug: Ticagrelor

Interventions

06

What researchers measure

Primary outcomes

  1. Bleeding Events

    PLATO-defined fatal/life threatening, major, major+minor,major+minor+minimal

    Time frame: 12 months

  2. Serious Adverse Events Other Than Bleeding

    SAEs except the blending events which have aleady been reported as SAEs.

    Time frame: 12 months

Secondary outcomes

  1. Major CV Events

    Combination of CV death, MI, and stroke

    Time frame: 12 months

07

Results

Posted Nov 9, 2016

Participant flow

Participant flow — Overall Study
MilestoneTicargrelor
Started2004
Completed1914
Not completed90
Withdrew: Subject decision80
Withdrew: Severe non-compliance to protocol7
Withdrew: Subject lost to follow up2
Withdrew: Other1

Outcome measures

PrimaryBleeding Events

PLATO-defined fatal/life threatening, major, major+minor,major+minor+minimal

Time frame:
12 months
Reported as:
Number · Participants
Bleeding Events
ParticipantsTicargrelor
Fatal/life threatening17
Major27
Major + minor93
Major + minor + minimal426
PrimarySerious Adverse Events Other Than Bleeding

SAEs except the blending events which have aleady been reported as SAEs.

Time frame:
12 months
Reported as:
Number · Participants
Serious Adverse Events Other Than Bleeding
ParticipantsTicargrelor
Serious Adverse Events Other Than Bleeding116
SecondaryMajor CV Events

Combination of CV death, MI, and stroke

Time frame:
12 months
Reported as:
Number · Participants
Major CV Events
ParticipantsTicargrelor
Major CV Events85

Adverse events

Collected over From day of first dose to the day of last dose + 7 days, up to 1 year.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ticargrelor—161/2,001 (8%)230/2,001 (11.5%)
Most frequent serious events
Showing 10 of 109
Most frequent serious events
EventTicargrelor
Upper Gastrointestinal HaemorrhageGastrointestinal disorders16/2001
Gastrointestinal HaemorrhageGastrointestinal disorders12/2001
Chest DiscomfortGeneral disorders6/2001
Cardiac FailureCardiac disorders5/2001
GastritisGastrointestinal disorders4/2001
Lung InfectionInfections and infestations4/2001
Chronic Kidney DiseaseRenal and urinary disorders4/2001
HaematuriaRenal and urinary disorders4/2001
Cerebral HaemorrhageNervous system disorders4/2001
Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders4/2001
Most frequent other events
Most frequent other events
EventTicargrelor
HyperuricaemiaMetabolism and nutrition disorders130/2001
EcchymosisSkin and subcutaneous tissue disorders113/2001

Baseline characteristics

Based on the safety population, i.e. all enrolled patients who received at least one dose of Investigational product (IP)

Age, Continuous
Age, Continuous(Years)Ticargrelor
Mean59.3 ± 10.83
Age, Customized
Age, Customized(Participants)Ticargrelor
< 75 years1854
>= 75 years147
Sex: Female, Male
Sex: Female, Male(Participants)Ticargrelor
Female422
Male1579
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ticargrelor
Hispanic or latino0
Not hispanic or latino2001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ticargrelor
Asian2001
Other0
08

Study locations

39 sites
  • Research Site
    Beijing, 100006, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100037, China
  • Research Site
    Beijing, 100050, China
  • Research Site
    Beijing, 100083, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chuangchun, 130041, China
  • Research Site
    Fuzhou, 350001, China
  • Research Site
    Fuzhou, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510220, China
  • Research Site
    Jinan, 250012, China
  • Research Site
    Jinan, 250021, China
  • Research Site
    Jinan, 250033, China
  • Research Site
    Jining, 272011, China
  • Research Site
    Kunming, 650032, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanjing, 210012, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Shanghai, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Shenyang, 110016, China
  • Research Site
    Shenzhen, 518003, China
  • Research Site
    Shenzhen, 518020, China
  • Research Site
    Shenzhen, 518036, China
  • Research Site
    Taiyuan, 030001, China
  • Research Site
    Wuhan, CN-430022, China
  • Research Site
    Wuxi, 214023, China
  • Research Site
    Xiamen, 361004, China
  • Research Site
    Xian, 710032, China
  • Research Site
    Xian, 710061, China
  • Research Site
    Xuzhou, 221006, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Zhengzhou, 450012, China
  • Research Site
    Zhongshan, 528403, China
09

References and documents

Publications

  • Gao R, Wu Y, Liu H, Su G, Yuan Z, Zhang A, Wang Y, Wang Z, Wang Y, Zhang H, Zheng Y, Liu L, Shen L, Leonsson-Zachrisson M, Han Y; DAYU study investigators. Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. Cardiovasc Drugs Ther. 2018 Feb;32(1):47-56. doi: 10.1007/s10557-018-6772-3. PubMed 29488142 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Sep 2015, 27 months.

Results were first posted in Nov 2016, 1 year 1 month after primary completion.

Of 92 phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2013
First posted
Jun 6, 2013
StartActual
Jun 26, 2013
Primary completionActual
Sep 30, 2015
CompletionActual
Sep 30, 2015
Results first posted
Nov 9, 2016
Last update
Apr 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01870921
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 6, 2013
Start date
Jun 26, 2013
Primary completion
Sep 30, 2015
Completion
Sep 30, 2015
Results posted
Nov 9, 2016
Last update
Apr 3, 2018

Study contacts

Runlin Gao, Doctor
principal investigator · Fu Wai Hospital, Beijing, China
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion